Your institution may have access to this item. Find your institution then sign in to continue.
Title
A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design.
Authors
Garon EB; Cao D; Alexandris E; John WJ; Yurasov S; Perol M